Lanreotide
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-LANREOTIDE |
|---|---|
| Type | Drug |
| Aliases | Somatuline AutogelSomatuline DepotЛанреотид |
| Status | reviewed 2026-05-03 | pending_clinical_signoff |
| Diseases | DIS-GI-NET |
| Sources | SRC-NCCN-NET-2025 |
Drug Facts
| Class | Somatostatin analogue (SSA) |
|---|---|
| Mechanism | Long-acting somatostatin analogue; high affinity for somatostatin receptor subtypes SSTR2 and SSTR5. Inhibits secretion of GH, IGF-1, insulin, glucagon, VIP, gastrin, and serotonin. Antiproliferative effect in well-differentiated GEP-NETs via SSTR2/SSTR5-mediated cell cycle arrest (CLARINET: HR 0.47 vs placebo). Symptom control in functional NETs (carcinoid syndrome: flushing, diarrhea). |
| Typical dosing | 120 mg SC deep subcutaneous injection every 4 weeks (q4w). Self-injection possible after training. Do not rub injection site. Alternate flanks/buttocks. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-03 |
Notes
CLARINET (Caplin NEJM 2014): lanreotide 120 mg q4w vs placebo in well-differentiated G1/G2 non-functioning GEP-NET (n=204). mPFS not reached vs 18.0 mo (HR 0.47, p<0.001). 96-week extension (CLARINET OLE) confirmed durable benefit. FDA approved lanreotide for non-functioning GEP-NET 2014. PROMID (Rinke JCO 2009) with octreotide LAR established SSA antiproliferative class effect for midgut NETs.
Used By
Regimens
REG-LANREOTIDE-AUTOGEL-GI-NET- Lanreotide Autogel 120 mg SC q4w (well-differentiated GEP-NET G1/G2; CLARINET)